NCT05911061View on ClinicalTrials.gov

A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

4,950

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions
COVID-19
Interventions
BIOLOGICAL

High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)

boost with high dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)

BIOLOGICAL

Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)

boost with low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)

BIOLOGICAL

control group

boost with Recombinant Variant COVID-19 Vaccine(sf9 cell)

BIOLOGICAL

Placebo group

saline

All Listed Sponsors
lead

WestVac Biopharma Co., Ltd.

INDUSTRY